sales@jinjingroup.com

  News Introduction

Vinpocetine(CAS 42971-09-5) combined with ginkgo dipyridamole in the treatment of acute cerebral infarction

Date : 2016/10/10 10:54:34

Cixi City, Zhejiang Province, Yokogawa Center Hospital researchers published papers to observe the vinpocetine(CAS 42971-09-5) combined with ginkgo dipyridamole in the treatment of acute cerebral infarction clinical efficacy. The study indicated that vinpocetine combined with Ginkgo biloba extract could improve the neurological deficit and improve the ability of daily living in patients with cerebral infarction, better than single drug therapy. The article published in the fifth of 2014, "Jilin Medical Journal".

Sixty patients with acute cerebral infarction were randomly divided into two groups: vinorelbine group, ginkgo dipyridamole group and combined treatment group, 20 cases in each group. The course of treatment was 14 days. The neurological deficits (CSS) and activities of daily living (ADL) were observed and the therapeutic effects were evaluated.

The total effective rate was 70.00%, 75.00%, 90.00% in vinpocetine(CAS 42971-09-5) group, Ginkgo biloba group and combination group, the difference was statistically significant (P <0.05).